Ocular Therapeutix, Inc. (OCUL)
OCUL Stock Price Chart
Explore Ocular Therapeutix, Inc. interactive price chart. Choose custom timeframes to analyze OCUL price movements and trends.
OCUL Company Profile
Discover essential business fundamentals and corporate details for Ocular Therapeutix, Inc. (OCUL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Jul 2014
Employees
274.00
Website
https://www.ocutx.comCEO
Pravin U. Dugel
Description
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
OCUL Financial Timeline
Browse a chronological timeline of Ocular Therapeutix, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.40, while revenue estimate is $13.20m.
Earnings released on 5 May 2026
EPS came in at -$0.41 falling short of the estimated -$0.32 by -28.12%, while revenue for the quarter reached $10.79m , missing expectations by -15.23%.
Earnings released on 5 Feb 2026
EPS came in at -$0.29 surpassing the estimated -$0.33 by +12.12%, while revenue for the quarter reached $13.25m , missing expectations by -17.85%.
Earnings released on 4 Nov 2025
EPS came in at -$0.37 surpassing the estimated -$0.39 by +5.13%, while revenue for the quarter reached $14.54m , missing expectations by -9.90%.
Earnings released on 5 Aug 2025
EPS came in at -$0.39 falling short of the estimated -$0.35 by -11.43%, while revenue for the quarter reached $13.46m , missing expectations by -7.60%.
Earnings released on 5 May 2025
EPS came in at -$0.37 falling short of the estimated -$0.29 by -27.59%, while revenue for the quarter reached $10.63m , missing expectations by -18.80%.
Earnings released on 3 Mar 2025
EPS came in at -$0.29 falling short of the estimated -$0.24 by -20.83%, while revenue for the quarter reached $17.08m , missing expectations by -0.17%.
Earnings released on 14 Nov 2024
EPS came in at -$0.26 falling short of the estimated -$0.23 by -13.04%, while revenue for the quarter reached $15.43m , missing expectations by -8.68%.
Earnings released on 7 Aug 2024
EPS came in at -$0.24 falling short of the estimated -$0.22 by -9.09%, while revenue for the quarter reached $16.44m , beating expectations by +3.93%.
Earnings released on 7 May 2024
EPS came in at -$0.24 falling short of the estimated -$0.18 by -33.33%, while revenue for the quarter reached $14.72m , missing expectations by -4.51%.
Earnings released on 11 Mar 2024
EPS came in at -$0.28 matching the estimated -$0.28, while revenue for the quarter reached $14.80m , missing expectations by -5.78%.
Earnings released on 7 Nov 2023
EPS came in at -$0.51 falling short of the estimated -$0.27 by -88.89%, while revenue for the quarter reached $14.95m , missing expectations by -5.80%.
Earnings released on 7 Aug 2023
EPS came in at -$0.27 surpassing the estimated -$0.29 by +6.90%, while revenue for the quarter reached $15.19m , beating expectations by +3.66%.
Earnings released on 8 May 2023
EPS came in at -$0.31 falling short of the estimated -$0.27 by -14.81%, while revenue for the quarter reached $13.37m , missing expectations by -5.15%.
Earnings released on 6 Mar 2023
EPS came in at -$0.24 surpassing the estimated -$0.25 by +4.00%, while revenue for the quarter reached $14.08m , beating expectations by +4.01%.
Earnings released on 7 Nov 2022
EPS came in at -$0.30 falling short of the estimated -$0.23 by -30.43%, while revenue for the quarter reached $11.97m , missing expectations by -16.16%.
Earnings released on 8 Aug 2022
EPS came in at -$0.28 falling short of the estimated -$0.23 by -21.74%, while revenue for the quarter reached $12.27m , missing expectations by -13.91%.
Earnings released on 9 May 2022
EPS came in at -$0.22 surpassing the estimated -$0.25 by +12.00%, while revenue for the quarter reached $13.19m , missing expectations by -5.52%.
Earnings released on 28 Feb 2022
EPS came in at -$0.23 matching the estimated -$0.23, while revenue for the quarter reached $12.31m , missing expectations by -11.71%.
Earnings released on 8 Nov 2021
EPS came in at -$0.23 surpassing the estimated -$0.26 by +11.54%, while revenue for the quarter reached $12.15m , missing expectations by -12.44%.
Earnings released on 9 Aug 2021
EPS came in at -$0.25 falling short of the estimated -$0.20 by -25.00%, while revenue for the quarter reached $11.72m , meeting expectations.
OCUL Stock Performance
Access detailed OCUL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
